• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Precipio Announces Q4 and year-end 2024 Shareholder Update Call

    3/17/25 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PRPO alert in real time by email

    NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses.

    The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10197585/fea81a2627 and will receive a calendar invite and a direct dial-in number, bypassing the operator.

    Listeners interested in submitting questions in advance should email their questions to [email protected] and management will do its best to address those questions during the call.

    A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio's website, https://www.precipiodx.com/investors/.

    About Precipio

    Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio's reach to eradicate misdiagnosis.

    Availability of Other Information About Precipio

    For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing.

    Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management's estimates, beliefs, assumptions and projections. Words such as "could," "may," "expects," "anticipates," "will," "targets," "goals," "projects," "intends," "plans," "believes," "seeks," "estimates," "predicts," and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management's estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.



    Inquiries:
    
    [email protected]
    
    +1-203-787-7888 Ext. 523

    Primary Logo

    Get the next $PRPO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sandberg Richard A was granted 2,946 shares, increasing direct ownership by 13% to 25,175 units (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      4/17/25 5:03:45 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Andrews Ronald Asbury was granted 1,785 shares, increasing direct ownership by 14% to 14,552 units (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      4/17/25 5:02:25 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Laporte Kathleen was granted 2,232 shares, increasing direct ownership by 22% to 12,303 units (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      4/17/25 5:01:38 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Financials

    Live finance-specific insights

    See more
    • Precipio Announces Q1-2025 Shareholder Update Call

      NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2025 corporate update call on May 15th, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio, Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10199645/ff1acc6c66 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions i

      5/1/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Announces Q4 and year-end 2024 Shareholder Update Call

      NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10197585/fea81a2627 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in su

      3/17/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

      NEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it has achieved two important financial goals in the last quarter of 2024: Positive Adjusted EBITDA – Precipio reports (unaudited) Adjusted EBITDA of $0.4M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense and other significant or non-operating (income) or expenses. Please see a detailed explanation at the bottom of this press release. Positive Cash flow. Precipio reports an (unaudited) increase of $0.3M in cash during Q4-2024. Of this improvement, $75,000 was due to directors' fees pai

      2/25/25 9:30:00 AM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    SEC Filings

    See more
    • Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Precipio, Inc. (0001043961) (Filer)

      5/6/25 4:00:22 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Precipio Inc.

      DEFA14A - Precipio, Inc. (0001043961) (Filer)

      4/30/25 2:00:41 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Precipio Inc.

      DEF 14A - Precipio, Inc. (0001043961) (Filer)

      4/30/25 2:00:26 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precipio Announces Q1-2025 Shareholder Update Call

      NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2025 corporate update call on May 15th, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio, Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10199645/ff1acc6c66 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions i

      5/1/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Announces Q4 and year-end 2024 Shareholder Update Call

      NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10197585/fea81a2627 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in su

      3/17/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

      NEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it has achieved two important financial goals in the last quarter of 2024: Positive Adjusted EBITDA – Precipio reports (unaudited) Adjusted EBITDA of $0.4M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense and other significant or non-operating (income) or expenses. Please see a detailed explanation at the bottom of this press release. Positive Cash flow. Precipio reports an (unaudited) increase of $0.3M in cash during Q4-2024. Of this improvement, $75,000 was due to directors' fees pai

      2/25/25 9:30:00 AM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Precipio Inc.

      SC 13G - Precipio, Inc. (0001043961) (Subject)

      8/2/24 2:15:53 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

      NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib

      3/21/22 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 89bio Announces Appointment of Kathy LaPorte to its Board of Directors

      SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien

      11/3/21 8:00:00 AM ET
      $BOLT
      $ETNB
      $PRPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

      NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f

      3/3/21 11:00:00 AM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Sabet Ahmed Zaki bought $474 worth of shares (79 units at $6.00), increasing direct ownership by 9% to 939 units (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      4/4/25 5:00:29 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: Director Sandberg Richard A sold $70,506 worth of shares (12,000 units at $5.88) and bought $91,430 worth of shares (15,000 units at $6.10), decreasing direct ownership by 73% to 4,525 units (SEC Form 4)

      4/A - Precipio, Inc. (0001043961) (Issuer)

      12/23/24 5:52:30 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Sandberg Richard A sold $74,400 worth of shares (12,000 units at $6.20) and bought $87,000 worth of shares (15,000 units at $5.80), decreasing direct ownership by 73% to 4,525 units (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      12/13/24 4:35:38 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials